ID   LSC_BACSU               Reviewed;         473 AA.
AC   P05655; P70984;
DT   01-NOV-1988, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1988, sequence version 1.
DT   18-JUN-2025, entry version 157.
DE   RecName: Full=Levansucrase {ECO:0000303|PubMed:4206083};
DE            EC=2.4.1.10 {ECO:0000269|PubMed:14517548, ECO:0000269|PubMed:18596022, ECO:0000269|PubMed:32553967, ECO:0000269|PubMed:33303628, ECO:0000269|PubMed:4206083};
DE   AltName: Full=Beta-D-fructofuranosyl transferase {ECO:0000303|PubMed:6424671};
DE   AltName: Full=Fructosyltransferase {ECO:0000303|PubMed:14517548};
DE            Short=FTF {ECO:0000303|PubMed:14517548};
DE   AltName: Full=Sucrose 6-fructosyl transferase;
DE   Flags: Precursor;
GN   Name=sacB {ECO:0000303|PubMed:6424671}; OrderedLocusNames=BSU34450;
OS   Bacillus subtilis (strain 168).
OC   Bacteria; Bacillati; Bacillota; Bacilli; Bacillales; Bacillaceae; Bacillus.
OX   NCBI_TaxID=224308;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND INDUCTION.
RC   STRAIN=168;
RX   PubMed=2993818; DOI=10.1007/bf00425427;
RA   Steinmetz M., Le Coq D., Aymerich S., Gonzy-Treboul G., Gay P.;
RT   "The DNA sequence of the gene for the secreted Bacillus subtilis enzyme
RT   levansucrase and its genetic control sites.";
RL   Mol. Gen. Genet. 200:220-228(1985).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RC   STRAIN=168;
RA   Denizot F.;
RL   Submitted (APR-1997) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=168;
RX   PubMed=9384377; DOI=10.1038/36786;
RA   Kunst F., Ogasawara N., Moszer I., Albertini A.M., Alloni G., Azevedo V.,
RA   Bertero M.G., Bessieres P., Bolotin A., Borchert S., Borriss R.,
RA   Boursier L., Brans A., Braun M., Brignell S.C., Bron S., Brouillet S.,
RA   Bruschi C.V., Caldwell B., Capuano V., Carter N.M., Choi S.-K.,
RA   Codani J.-J., Connerton I.F., Cummings N.J., Daniel R.A., Denizot F.,
RA   Devine K.M., Duesterhoeft A., Ehrlich S.D., Emmerson P.T., Entian K.-D.,
RA   Errington J., Fabret C., Ferrari E., Foulger D., Fritz C., Fujita M.,
RA   Fujita Y., Fuma S., Galizzi A., Galleron N., Ghim S.-Y., Glaser P.,
RA   Goffeau A., Golightly E.J., Grandi G., Guiseppi G., Guy B.J., Haga K.,
RA   Haiech J., Harwood C.R., Henaut A., Hilbert H., Holsappel S., Hosono S.,
RA   Hullo M.-F., Itaya M., Jones L.-M., Joris B., Karamata D., Kasahara Y.,
RA   Klaerr-Blanchard M., Klein C., Kobayashi Y., Koetter P., Koningstein G.,
RA   Krogh S., Kumano M., Kurita K., Lapidus A., Lardinois S., Lauber J.,
RA   Lazarevic V., Lee S.-M., Levine A., Liu H., Masuda S., Mauel C.,
RA   Medigue C., Medina N., Mellado R.P., Mizuno M., Moestl D., Nakai S.,
RA   Noback M., Noone D., O'Reilly M., Ogawa K., Ogiwara A., Oudega B.,
RA   Park S.-H., Parro V., Pohl T.M., Portetelle D., Porwollik S.,
RA   Prescott A.M., Presecan E., Pujic P., Purnelle B., Rapoport G., Rey M.,
RA   Reynolds S., Rieger M., Rivolta C., Rocha E., Roche B., Rose M., Sadaie Y.,
RA   Sato T., Scanlan E., Schleich S., Schroeter R., Scoffone F., Sekiguchi J.,
RA   Sekowska A., Seror S.J., Serror P., Shin B.-S., Soldo B., Sorokin A.,
RA   Tacconi E., Takagi T., Takahashi H., Takemaru K., Takeuchi M.,
RA   Tamakoshi A., Tanaka T., Terpstra P., Tognoni A., Tosato V., Uchiyama S.,
RA   Vandenbol M., Vannier F., Vassarotti A., Viari A., Wambutt R., Wedler E.,
RA   Wedler H., Weitzenegger T., Winters P., Wipat A., Yamamoto H., Yamane K.,
RA   Yasumoto K., Yata K., Yoshida K., Yoshikawa H.-F., Zumstein E.,
RA   Yoshikawa H., Danchin A.;
RT   "The complete genome sequence of the Gram-positive bacterium Bacillus
RT   subtilis.";
RL   Nature 390:249-256(1997).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-62.
RC   STRAIN=168 / PY79;
RX   PubMed=6424671; DOI=10.1016/s0006-291x(84)80320-4;
RA   Fouet A., Arnaud M., Klier A., Rapoport G.;
RT   "Characterization of the precursor form of the exocellular levansucrase
RT   from Bacillus subtilis.";
RL   Biochem. Biophys. Res. Commun. 119:795-800(1984).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-68, AND INDUCTION.
RX   PubMed=2428811; DOI=10.1128/jb.168.1.380-388.1986;
RA   Shimotsu H., Henner D.J.;
RT   "Modulation of Bacillus subtilis levansucrase gene expression by sucrose
RT   and regulation of the steady-state mRNA level by sacU and sacQ genes.";
RL   J. Bacteriol. 168:380-388(1986).
RN   [6]
RP   FUNCTION, AND CATALYTIC ACTIVITY.
RX   PubMed=4206083; DOI=10.1111/j.1432-1033.1974.tb03269.x;
RA   Chambert R., Treboul G., Dedonder R.;
RT   "Kinetic studies of levansucrase of Bacillus subtilis.";
RL   Eur. J. Biochem. 41:285-300(1974).
RN   [7]
RP   SUBUNIT, AND AMINO ACID COMPOSITION.
RX   PubMed=807261; DOI=10.1016/s0300-9084(75)80105-2;
RA   Gonzy-Treboul G., Chambert R., Dedonder R.;
RT   "Levansucrase of Bacillus subtilis: reexamination of some physical and
RT   chemical properties.";
RL   Biochimie 57:17-28(1975).
RN   [8]
RP   INDUCTION.
RX   PubMed=11739774; DOI=10.1099/00221287-147-12-3413;
RA   Pereira Y., Petit-Glatron M.-F., Chambert R.;
RT   "yveB, encoding endolevanase LevB, is part of the sacB-yveB-yveA
RT   levansucrase tricistronic operon in Bacillus subtilis.";
RL   Microbiology 147:3413-3419(2001).
RN   [9]
RP   ACTIVITY REGULATION.
RC   STRAIN=168;
RX   PubMed=26256357; DOI=10.1016/j.carbpol.2015.06.056;
RA   Porras-Dominguez J.R., Avila-Fernandez A., Miranda-Molina A.,
RA   Rodriguez-Alegria M.E., Munguia A.L.;
RT   "Bacillus subtilis 168 levansucrase (SacB) activity affects average levan
RT   molecular weight.";
RL   Carbohydr. Polym. 132:338-344(2015).
RN   [10] {ECO:0007744|PDB:1OYG, ECO:0007744|PDB:1PT2}
RP   X-RAY CRYSTALLOGRAPHY (1.50 ANGSTROMS) OF 30-473 IN COMPLEX WITH CA(2+) AND
RP   OF MUTANT ALA-342 IN COMPLEX WITH CA(2+) AND SUCROSE, FUNCTION, CATALYTIC
RP   ACTIVITY, ACTIVITY REGULATION, ACTIVE SITE, AND MUTAGENESIS OF ASP-86;
RP   ASP-247 AND GLU-342.
RX   PubMed=14517548; DOI=10.1038/nsb974;
RA   Meng G., Futterer K.;
RT   "Structural framework of fructosyl transfer in Bacillus subtilis
RT   levansucrase.";
RL   Nat. Struct. Biol. 10:935-941(2003).
RN   [11] {ECO:0007744|PDB:2VDT}
RP   X-RAY CRYSTALLOGRAPHY (3.20 ANGSTROMS) OF 34-472 OF MUTANT ALA-164 IN
RP   COMPLEX WITH CA(2+), FUNCTION, CATALYTIC ACTIVITY, BIOPHYSICOCHEMICAL
RP   PROPERTIES, AND MUTAGENESIS OF SER-164; HIS-243; ILE-341; ALA-344; ARG-360;
RP   GLY-361; PHE-414; TYR-429 AND ARG-433.
RX   PubMed=18596022; DOI=10.1093/protein/gzn036;
RA   Ortiz-Soto M.E., Rivera M., Rudino-Pinera E., Olvera C., Lopez-Munguia A.;
RT   "Selected mutations in Bacillus subtilis levansucrase semi-conserved
RT   regions affecting its biochemical properties.";
RL   Protein Eng. Des. Sel. 21:589-595(2008).
RN   [12] {ECO:0007744|PDB:3BYJ, ECO:0007744|PDB:3BYK, ECO:0007744|PDB:3BYL, ECO:0007744|PDB:3BYN}
RP   X-RAY CRYSTALLOGRAPHY (2.10 ANGSTROMS) OF MUTANTS ALA-86; ALA-247 AND
RP   ALA-342 IN COMPLEXES WITH CA(2+) AND RAFFINOSE.
RA   Meng G., Futterer K.;
RT   "Donor substrate recognition in the raffinose-bound E342A mutant of
RT   fructosyltransferase Bacillus subtilis levansucrase.";
RL   Submitted (JAN-2008) to the PDB data bank.
RN   [13] {ECO:0007744|PDB:6PWQ}
RP   X-RAY CRYSTALLOGRAPHY (2.60 ANGSTROMS) OF 30-473 OF MUTANT ALA-164 IN
RP   COMPLEX WITH CA(2+), FUNCTION, CATALYTIC ACTIVITY, BIOPHYSICOCHEMICAL
RP   PROPERTIES, AND MUTAGENESIS OF SER-164.
RX   PubMed=32553967; DOI=10.1016/j.ijbiomac.2020.06.114;
RA   Ortiz-Soto M.E., Porras-Dominguez J.R., Rodriguez-Alegria M.E.,
RA   Morales-Moreno L.A., Diaz-Vilchis A., Rudino-Pinera E.,
RA   Beltran-Hernandez N.E., Rivera H.M., Seibel J., Lopez Munguia A.;
RT   "Implications of the mutation S164A on Bacillus subtilis levansucrase
RT   product specificity and insights into protein interactions acting upon
RT   levan synthesis.";
RL   Int. J. Biol. Macromol. 161:898-908(2020).
RN   [14] {ECO:0007744|PDB:6VHQ}
RP   X-RAY CRYSTALLOGRAPHY (2.05 ANGSTROMS) OF 30-473 OF MUTANT ALA-86/ALA-342
RP   IN COMPLEX WITH CA(2+) AND LEVAN-TYPE HEXASACCHARIDES, FUNCTION, CATALYTIC
RP   ACTIVITY, BIOPHYSICOCHEMICAL PROPERTIES, AND MUTAGENESIS OF ASP-117;
RP   PHE-182; TYR-187; TYR-237; ASN-242 AND LYS-363.
RX   PubMed=33303628; DOI=10.1074/jbc.ra120.015853;
RA   Raga-Carbajal E., Diaz-Vilchis A., Rojas-Trejo S.P., Rudino-Pinera E.,
RA   Olvera C.;
RT   "The molecular basis of the nonprocessive elongation mechanism in
RT   levansucrases.";
RL   J. Biol. Chem. 296:100178-100178(2021).
CC   -!- FUNCTION: Catalyzes the synthesis of levan, a fructose polymer, by
CC       transferring the fructosyl moiety from sucrose to a growing acceptor
CC       molecule (PubMed:14517548, PubMed:18596022, PubMed:32553967,
CC       PubMed:33303628, PubMed:4206083). Also displays sucrose hydrolase
CC       activity (PubMed:18596022, PubMed:32553967, PubMed:33303628,
CC       PubMed:4206083). At low sucrose concentrations, functions as an
CC       hydrolase with water as acceptor, whereas at higher substrate
CC       concentrations it adds fructosyl units to a growing levan chain
CC       (PubMed:4206083). {ECO:0000269|PubMed:14517548,
CC       ECO:0000269|PubMed:18596022, ECO:0000269|PubMed:32553967,
CC       ECO:0000269|PubMed:33303628, ECO:0000269|PubMed:4206083}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=[6)-beta-D-fructofuranosyl-(2->](n) alpha-D-glucopyranoside +
CC         sucrose = [6)-beta-D-fructofuranosyl-(2->](n+1) alpha-D-
CC         glucopyranoside + D-glucose; Xref=Rhea:RHEA:13653, Rhea:RHEA-
CC         COMP:13093, Rhea:RHEA-COMP:13094, ChEBI:CHEBI:4167,
CC         ChEBI:CHEBI:17992, ChEBI:CHEBI:134464; EC=2.4.1.10;
CC         Evidence={ECO:0000269|PubMed:14517548, ECO:0000269|PubMed:18596022,
CC         ECO:0000269|PubMed:32553967, ECO:0000269|PubMed:33303628,
CC         ECO:0000269|PubMed:4206083};
CC   -!- ACTIVITY REGULATION: Ca(2+) may play an important structural role and
CC       promote stability of levansucrase (PubMed:14517548). The enzyme
CC       concentration is a factor defining the molecular weight (MW) levan
CC       distribution (PubMed:26256357). A bimodal distribution is reported at
CC       the usual enzyme concentrations (PubMed:26256357). At low
CC       concentrations, the enzyme synthesizes high MW levan, and at high
CC       concentrations, it synthesizes low MW levan (PubMed:26256357).
CC       {ECO:0000269|PubMed:14517548, ECO:0000269|PubMed:26256357}.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=8 mM for sucrose {ECO:0000269|PubMed:18596022};
CC         KM=9 mM for sucrose {ECO:0000269|PubMed:33303628};
CC         KM=8.3 mM for sucrose (for hydrolysis, in the absence of levan F4)
CC         {ECO:0000269|PubMed:32553967};
CC         KM=6.9 mM for sucrose (for hydrolysis, in the presence of 5 g/L levan
CC         F4) {ECO:0000269|PubMed:32553967};
CC         KM=6.8 mM for sucrose (for hydrolysis, in the presence of 55 g/L
CC         levan F4) {ECO:0000269|PubMed:32553967};
CC         KM=57.6 mM for sucrose (for transfructosylation, in the absence of
CC         levan F4) {ECO:0000269|PubMed:32553967};
CC         KM=20.9 mM for sucrose (for transfructosylation, in the presence of 5
CC         g/L levan F4) {ECO:0000269|PubMed:32553967};
CC         KM=10.9 mM for sucrose (for transfructosylation, in the presence of
CC         55 g/L levan F4) {ECO:0000269|PubMed:32553967};
CC         Note=kcat is 164.6 sec(-1) with sucrose as substrate
CC         (PubMed:18596022). kcat is 236.7 sec(-1) with sucrose as substrate
CC         (PubMed:33303628). kcat is 71.2 sec(-1) with sucrose as substrate
CC         (for hydrolysis, in the absence of levan F4). kcat is 69.8 sec(-1)
CC         with sucrose as substrate (for hydrolysis, in the presence of 5 g/L
CC         levan F4). kcat is 65.9 sec(-1) with sucrose as substrate (for
CC         hydrolysis, in the presence of 55 g/L levan F4). kcat is 26.6 sec(-1)
CC         with sucrose as substrate (for transfructosylation, in the absence of
CC         levan F4). kcat is 33.0 sec(-1) with sucrose as substrate (for
CC         transfructosylation, in the presence of 5 g/L levan F4). kcat is 33.7
CC         sec(-1) with sucrose as substrate (for transfructosylation, in the
CC         presence of 55 g/L levan F4) (PubMed:32553967).
CC         {ECO:0000269|PubMed:18596022, ECO:0000269|PubMed:32553967,
CC         ECO:0000269|PubMed:33303628};
CC       pH dependence:
CC         Optimum pH is 6. {ECO:0000269|PubMed:18596022};
CC   -!- SUBUNIT: Monomer. {ECO:0000269|PubMed:807261}.
CC   -!- SUBCELLULAR LOCATION: Secreted {ECO:0000305}.
CC   -!- INDUCTION: Induced by sucrose (PubMed:11739774, PubMed:2428811).
CC       Expression is controlled by the sacR non-coding regulatory region,
CC       located upstream from sacB (PubMed:2428811, PubMed:2993818).
CC       {ECO:0000269|PubMed:11739774, ECO:0000269|PubMed:2428811,
CC       ECO:0000269|PubMed:2993818}.
CC   -!- SIMILARITY: Belongs to the glycosyl hydrolase 68 family. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; M14202; AAA22725.1; -; Genomic_DNA.
DR   EMBL; Z94043; CAB08015.1; -; Genomic_DNA.
DR   EMBL; AL009126; CAB15450.1; -; Genomic_DNA.
DR   EMBL; K01987; AAA22724.1; -; Genomic_DNA.
DR   EMBL; X02730; CAA26513.1; -; Genomic_DNA.
DR   PIR; S07309; A25040.
DR   RefSeq; NP_391325.1; NC_000964.3.
DR   RefSeq; WP_001022105.1; NZ_OZ025638.1.
DR   PDB; 1OYG; X-ray; 1.50 A; A=30-473.
DR   PDB; 1PT2; X-ray; 2.10 A; A=30-473.
DR   PDB; 2VDT; X-ray; 3.20 A; A=34-472.
DR   PDB; 3BYJ; X-ray; 2.10 A; A=1-473.
DR   PDB; 3BYK; X-ray; 2.10 A; A=1-473.
DR   PDB; 3BYL; X-ray; 2.10 A; A=1-473.
DR   PDB; 3BYN; X-ray; 2.10 A; A=1-473.
DR   PDB; 6PWQ; X-ray; 2.60 A; A/B=30-473.
DR   PDB; 6VHQ; X-ray; 2.05 A; A/B=30-473.
DR   PDBsum; 1OYG; -.
DR   PDBsum; 1PT2; -.
DR   PDBsum; 2VDT; -.
DR   PDBsum; 3BYJ; -.
DR   PDBsum; 3BYK; -.
DR   PDBsum; 3BYL; -.
DR   PDBsum; 3BYN; -.
DR   PDBsum; 6PWQ; -.
DR   PDBsum; 6VHQ; -.
DR   AlphaFoldDB; P05655; -.
DR   SMR; P05655; -.
DR   FunCoup; P05655; 203.
DR   STRING; 224308.BSU34450; -.
DR   DrugBank; DB02772; Sucrose.
DR   CAZy; GH68; Glycoside Hydrolase Family 68.
DR   PaxDb; 224308-BSU34450; -.
DR   EnsemblBacteria; CAB15450; CAB15450; BSU_34450.
DR   GeneID; 936413; -.
DR   KEGG; bsu:BSU34450; -.
DR   PATRIC; fig|224308.179.peg.3732; -.
DR   eggNOG; COG1621; Bacteria.
DR   InParanoid; P05655; -.
DR   OrthoDB; 2210426at2; -.
DR   PhylomeDB; P05655; -.
DR   BioCyc; BSUB:BSU34450-MONOMER; -.
DR   BioCyc; MetaCyc:BSU34450-MONOMER; -.
DR   BRENDA; 2.4.1.10; 658.
DR   SABIO-RK; P05655; -.
DR   EvolutionaryTrace; P05655; -.
DR   Proteomes; UP000001570; Chromosome.
DR   GO; GO:0005576; C:extracellular region; IEA:UniProtKB-SubCell.
DR   GO; GO:0050053; F:levansucrase activity; IEA:UniProtKB-EC.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0009758; P:carbohydrate utilization; IEA:InterPro.
DR   CDD; cd08997; GH68; 1.
DR   Gene3D; 2.115.10.20; Glycosyl hydrolase domain, family 43; 1.
DR   InterPro; IPR003469; Glyco_hydro_68.
DR   InterPro; IPR023296; Glyco_hydro_beta-prop_sf.
DR   Pfam; PF02435; Glyco_hydro_68; 1.
DR   SUPFAM; SSF75005; Arabinanase/levansucrase/invertase; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Calcium; Carbohydrate metabolism; Glycosyltransferase;
KW   Metal-binding; Reference proteome; Secreted; Signal; Transferase.
FT   SIGNAL          1..29
FT                   /evidence="ECO:0000305|PubMed:6424671"
FT   CHAIN           30..473
FT                   /note="Levansucrase"
FT                   /id="PRO_0000012249"
FT   ACT_SITE        86
FT                   /note="Nucleophile"
FT                   /evidence="ECO:0000305|PubMed:14517548"
FT   ACT_SITE        342
FT                   /note="Proton donor/acceptor"
FT                   /evidence="ECO:0000305|PubMed:14517548"
FT   BINDING         85
FT                   /ligand="sucrose"
FT                   /ligand_id="ChEBI:CHEBI:17992"
FT                   /evidence="ECO:0000269|PubMed:14517548,
FT                   ECO:0007744|PDB:1PT2, ECO:0007744|PDB:3BYN"
FT   BINDING         86
FT                   /ligand="sucrose"
FT                   /ligand_id="ChEBI:CHEBI:17992"
FT                   /evidence="ECO:0000269|PubMed:14517548,
FT                   ECO:0007744|PDB:1PT2, ECO:0007744|PDB:3BYN"
FT   BINDING         164
FT                   /ligand="sucrose"
FT                   /ligand_id="ChEBI:CHEBI:17992"
FT                   /evidence="ECO:0000269|PubMed:14517548,
FT                   ECO:0007744|PDB:1PT2, ECO:0007744|PDB:3BYN"
FT   BINDING         241
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /evidence="ECO:0000269|PubMed:14517548,
FT                   ECO:0000269|PubMed:18596022, ECO:0000269|PubMed:32553967,
FT                   ECO:0000269|PubMed:33303628, ECO:0007744|PDB:1OYG,
FT                   ECO:0007744|PDB:1PT2, ECO:0007744|PDB:2VDT,
FT                   ECO:0007744|PDB:3BYJ, ECO:0007744|PDB:3BYK,
FT                   ECO:0007744|PDB:3BYN, ECO:0007744|PDB:6PWQ,
FT                   ECO:0007744|PDB:6VHQ"
FT   BINDING         246
FT                   /ligand="sucrose"
FT                   /ligand_id="ChEBI:CHEBI:17992"
FT                   /evidence="ECO:0000269|PubMed:14517548,
FT                   ECO:0007744|PDB:1PT2, ECO:0007744|PDB:3BYN"
FT   BINDING         247
FT                   /ligand="sucrose"
FT                   /ligand_id="ChEBI:CHEBI:17992"
FT                   /evidence="ECO:0000269|PubMed:14517548,
FT                   ECO:0007744|PDB:1PT2, ECO:0007744|PDB:3BYN"
FT   BINDING         272
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /evidence="ECO:0000269|PubMed:14517548,
FT                   ECO:0000269|PubMed:18596022, ECO:0000269|PubMed:32553967,
FT                   ECO:0000269|PubMed:33303628, ECO:0007744|PDB:1OYG,
FT                   ECO:0007744|PDB:1PT2, ECO:0007744|PDB:2VDT,
FT                   ECO:0007744|PDB:3BYJ, ECO:0007744|PDB:3BYK,
FT                   ECO:0007744|PDB:3BYN, ECO:0007744|PDB:6PWQ,
FT                   ECO:0007744|PDB:6VHQ"
FT   BINDING         308
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /evidence="ECO:0000269|PubMed:14517548,
FT                   ECO:0000269|PubMed:18596022, ECO:0000269|PubMed:32553967,
FT                   ECO:0000269|PubMed:33303628, ECO:0007744|PDB:1OYG,
FT                   ECO:0007744|PDB:1PT2, ECO:0007744|PDB:2VDT,
FT                   ECO:0007744|PDB:3BYJ, ECO:0007744|PDB:3BYK,
FT                   ECO:0007744|PDB:3BYN, ECO:0007744|PDB:6PWQ,
FT                   ECO:0007744|PDB:6VHQ"
FT   BINDING         310
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /evidence="ECO:0000269|PubMed:14517548,
FT                   ECO:0000269|PubMed:18596022, ECO:0000269|PubMed:32553967,
FT                   ECO:0000269|PubMed:33303628, ECO:0007744|PDB:1OYG,
FT                   ECO:0007744|PDB:1PT2, ECO:0007744|PDB:2VDT,
FT                   ECO:0007744|PDB:3BYJ, ECO:0007744|PDB:3BYK,
FT                   ECO:0007744|PDB:3BYN, ECO:0007744|PDB:6PWQ,
FT                   ECO:0007744|PDB:6VHQ"
FT   BINDING         339
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /evidence="ECO:0000269|PubMed:14517548,
FT                   ECO:0000269|PubMed:18596022, ECO:0000269|PubMed:32553967,
FT                   ECO:0000269|PubMed:33303628, ECO:0007744|PDB:1OYG,
FT                   ECO:0007744|PDB:1PT2, ECO:0007744|PDB:2VDT,
FT                   ECO:0007744|PDB:3BYJ, ECO:0007744|PDB:3BYK,
FT                   ECO:0007744|PDB:3BYN, ECO:0007744|PDB:6PWQ,
FT                   ECO:0007744|PDB:6VHQ"
FT   BINDING         340
FT                   /ligand="sucrose"
FT                   /ligand_id="ChEBI:CHEBI:17992"
FT                   /evidence="ECO:0000269|PubMed:14517548,
FT                   ECO:0007744|PDB:1PT2, ECO:0007744|PDB:3BYN"
FT   BINDING         360
FT                   /ligand="sucrose"
FT                   /ligand_id="ChEBI:CHEBI:17992"
FT                   /evidence="ECO:0000269|PubMed:14517548,
FT                   ECO:0007744|PDB:1PT2, ECO:0007744|PDB:3BYN"
FT   SITE            247
FT                   /note="Transition state stabilizer"
FT                   /evidence="ECO:0000305|PubMed:14517548"
FT   MUTAGEN         86
FT                   /note="D->A: Lack of levan synthesis."
FT                   /evidence="ECO:0000269|PubMed:14517548"
FT   MUTAGEN         117
FT                   /note="D->A: 2-fold decrease in catalytic efficiency.
FT                   Synthesizes a bimodal levan molecular weight distribution."
FT                   /evidence="ECO:0000269|PubMed:33303628"
FT   MUTAGEN         164
FT                   /note="S->A: Drastic decrease in catalytic efficiency.
FT                   Slight increase in affinity for sucrose. Increases
FT                   transfructosylation activity. Uses acceptors such as
FT                   glucose and short levans with an average molecular weight
FT                   of 7.6 kDa more efficiently than wild-type enzyme, leading
FT                   to the enhanced synthesis of medium and high molecular
FT                   weight polymer."
FT                   /evidence="ECO:0000269|PubMed:18596022,
FT                   ECO:0000269|PubMed:32553967"
FT   MUTAGEN         164
FT                   /note="S->K: Loss of activity."
FT                   /evidence="ECO:0000269|PubMed:18596022"
FT   MUTAGEN         182
FT                   /note="F->A: 3.7-fold decrease in catalytic efficiency.
FT                   1.6-fold increase in KM for sucrose. Synthesizes only high
FT                   molecular weight levans."
FT                   /evidence="ECO:0000269|PubMed:33303628"
FT   MUTAGEN         182
FT                   /note="F->W: 2.1-fold decrease in catalytic efficiency.
FT                   Synthesizes a bimodal levan molecular weight distribution."
FT                   /evidence="ECO:0000269|PubMed:33303628"
FT   MUTAGEN         182
FT                   /note="F->Y: 1.7-fold decrease in catalytic efficiency.
FT                   Synthesizes a bimodal levan molecular weight distribution."
FT                   /evidence="ECO:0000269|PubMed:33303628"
FT   MUTAGEN         187
FT                   /note="Y->A: Slight decrease in catalytic efficiency.
FT                   Synthesizes a bimodal levan molecular weight distribution."
FT                   /evidence="ECO:0000269|PubMed:33303628"
FT   MUTAGEN         237
FT                   /note="Y->A: Slight decrease in catalytic efficiency.
FT                   Synthesizes only high molecular weight levans."
FT                   /evidence="ECO:0000269|PubMed:33303628"
FT   MUTAGEN         242
FT                   /note="N->A: 14.6-fold decrease in catalytic efficiency.
FT                   2.2-fold increase in KM for sucrose. Levans are barely
FT                   formed."
FT                   /evidence="ECO:0000269|PubMed:33303628"
FT   MUTAGEN         243
FT                   /note="H->L: Decrease in catalytic efficiency."
FT                   /evidence="ECO:0000269|PubMed:18596022"
FT   MUTAGEN         247
FT                   /note="D->A: Lack of levan synthesis."
FT                   /evidence="ECO:0000269|PubMed:14517548"
FT   MUTAGEN         341
FT                   /note="I->V: Increases transfructosylation activity."
FT                   /evidence="ECO:0000269|PubMed:18596022"
FT   MUTAGEN         342
FT                   /note="E->A: Lack of levan synthesis."
FT                   /evidence="ECO:0000269|PubMed:14517548"
FT   MUTAGEN         344
FT                   /note="A->P: Increases transfructosylation activity."
FT                   /evidence="ECO:0000269|PubMed:18596022"
FT   MUTAGEN         360
FT                   /note="R->K: Decrease in catalytic efficiency. Reduces
FT                   affinity for sucrose. Synthesizes mainly oligosaccharides,
FT                   but can still catalyze the synthesis of low amounts of
FT                   levan."
FT                   /evidence="ECO:0000269|PubMed:18596022"
FT   MUTAGEN         360
FT                   /note="R->S: Drastic decrease in catalytic efficiency.
FT                   Reduces affinity for sucrose. Synthesizes only
FT                   oligosaccharides."
FT                   /evidence="ECO:0000269|PubMed:18596022"
FT   MUTAGEN         361
FT                   /note="G->F: Drastic decrease in catalytic efficiency.
FT                   Reduces affinity for sucrose. Synthesizes mainly
FT                   oligosaccharides, but can still catalyze the synthesis of
FT                   low amounts of levan."
FT                   /evidence="ECO:0000269|PubMed:18596022"
FT   MUTAGEN         363
FT                   /note="K->A: 2.9-fold decrease in catalytic efficiency.
FT                   Synthesizes only high molecular weight levans."
FT                   /evidence="ECO:0000269|PubMed:33303628"
FT   MUTAGEN         414
FT                   /note="F->W: Increases transfructosylation activity."
FT                   /evidence="ECO:0000269|PubMed:18596022"
FT   MUTAGEN         429
FT                   /note="Y->N: Drastic decrease in catalytic efficiency.
FT                   Reduces affinity for sucrose. Synthesizes only
FT                   oligosaccharides."
FT                   /evidence="ECO:0000269|PubMed:18596022"
FT   MUTAGEN         433
FT                   /note="R->A: Drastic decrease in catalytic efficiency.
FT                   Reduces affinity for sucrose. Synthesizes only
FT                   oligosaccharides."
FT                   /evidence="ECO:0000269|PubMed:18596022"
FT   CONFLICT        12
FT                   /note="V -> I (in Ref. 4; AAA22724)"
FT                   /evidence="ECO:0000305"
FT   STRAND          43..45
FT                   /evidence="ECO:0007829|PDB:1OYG"
FT   HELIX           48..52
FT                   /evidence="ECO:0007829|PDB:1OYG"
FT   HELIX           54..57
FT                   /evidence="ECO:0007829|PDB:1OYG"
FT   HELIX           61..63
FT                   /evidence="ECO:0007829|PDB:1OYG"
FT   HELIX           70..72
FT                   /evidence="ECO:0007829|PDB:1OYG"
FT   HELIX           77..79
FT                   /evidence="ECO:0007829|PDB:1OYG"
FT   STRAND          83..91
FT                   /evidence="ECO:0007829|PDB:1OYG"
FT   STRAND          95..97
FT                   /evidence="ECO:0007829|PDB:1OYG"
FT   STRAND          103..111
FT                   /evidence="ECO:0007829|PDB:1OYG"
FT   STRAND          120..127
FT                   /evidence="ECO:0007829|PDB:1OYG"
FT   HELIX           133..135
FT                   /evidence="ECO:0007829|PDB:1OYG"
FT   STRAND          137..142
FT                   /evidence="ECO:0007829|PDB:1OYG"
FT   HELIX           147..150
FT                   /evidence="ECO:0007829|PDB:1OYG"
FT   HELIX           156..158
FT                   /evidence="ECO:0007829|PDB:1OYG"
FT   STRAND          161..169
FT                   /evidence="ECO:0007829|PDB:1OYG"
FT   STRAND          175..183
FT                   /evidence="ECO:0007829|PDB:1OYG"
FT   TURN            184..188
FT                   /evidence="ECO:0007829|PDB:1OYG"
FT   STRAND          189..201
FT                   /evidence="ECO:0007829|PDB:1OYG"
FT   STRAND          206..218
FT                   /evidence="ECO:0007829|PDB:1OYG"
FT   STRAND          222..225
FT                   /evidence="ECO:0007829|PDB:1OYG"
FT   HELIX           228..234
FT                   /evidence="ECO:0007829|PDB:1OYG"
FT   HELIX           236..239
FT                   /evidence="ECO:0007829|PDB:1OYG"
FT   STRAND          246..253
FT                   /evidence="ECO:0007829|PDB:1OYG"
FT   STRAND          256..265
FT                   /evidence="ECO:0007829|PDB:1OYG"
FT   STRAND          267..270
FT                   /evidence="ECO:0007829|PDB:6PWQ"
FT   HELIX           274..278
FT                   /evidence="ECO:0007829|PDB:1OYG"
FT   HELIX           280..282
FT                   /evidence="ECO:0007829|PDB:1OYG"
FT   HELIX           287..299
FT                   /evidence="ECO:0007829|PDB:1OYG"
FT   HELIX           303..308
FT                   /evidence="ECO:0007829|PDB:1OYG"
FT   STRAND          311..318
FT                   /evidence="ECO:0007829|PDB:1OYG"
FT   STRAND          322..333
FT                   /evidence="ECO:0007829|PDB:1OYG"
FT   TURN            335..337
FT                   /evidence="ECO:0007829|PDB:1OYG"
FT   STRAND          342..349
FT                   /evidence="ECO:0007829|PDB:1OYG"
FT   STRAND          352..360
FT                   /evidence="ECO:0007829|PDB:1OYG"
FT   HELIX           361..363
FT                   /evidence="ECO:0007829|PDB:1OYG"
FT   STRAND          374..383
FT                   /evidence="ECO:0007829|PDB:1OYG"
FT   HELIX           391..393
FT                   /evidence="ECO:0007829|PDB:1OYG"
FT   STRAND          395..400
FT                   /evidence="ECO:0007829|PDB:1OYG"
FT   STRAND          404..406
FT                   /evidence="ECO:0007829|PDB:2VDT"
FT   STRAND          410..416
FT                   /evidence="ECO:0007829|PDB:1OYG"
FT   STRAND          419..431
FT                   /evidence="ECO:0007829|PDB:1OYG"
FT   STRAND          435..438
FT                   /evidence="ECO:0007829|PDB:2VDT"
FT   STRAND          441..443
FT                   /evidence="ECO:0007829|PDB:6VHQ"
FT   STRAND          447..452
FT                   /evidence="ECO:0007829|PDB:1OYG"
FT   STRAND          455..458
FT                   /evidence="ECO:0007829|PDB:1OYG"
SQ   SEQUENCE   473 AA;  52971 MW;  3FBF2F571B41D5B0 CRC64;
     MNIKKFAKQA TVLTFTTALL AGGATQAFAK ETNQKPYKET YGISHITRHD MLQIPEQQKN
     EKYQVPEFDS STIKNISSAK GLDVWDSWPL QNADGTVANY HGYHIVFALA GDPKNADDTS
     IYMFYQKVGE TSIDSWKNAG RVFKDSDKFD ANDSILKDQT QEWSGSATFT SDGKIRLFYT
     DFSGKHYGKQ TLTTAQVNVS ASDSSLNING VEDYKSIFDG DGKTYQNVQQ FIDEGNYSSG
     DNHTLRDPHY VEDKGHKYLV FEANTGTEDG YQGEESLFNK AYYGKSTSFF RQESQKLLQS
     DKKRTAELAN GALGMIELND DYTLKKVMKP LIASNTVTDE IERANVFKMN GKWYLFTDSR
     GSKMTIDGIT SNDIYMLGYV SNSLTGPYKP LNKTGLVLKM DLDPNDVTFT YSHFAVPQAK
     GNNVVITSYM TNRGFYADKQ STFAPSFLLN IKGKKTSVVK DSILEQGQLT VNK
//
